Erratum: Expression of Concern: Overexpression of miR-142-5p and miR-155 in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Resistant to Helicobacter pylori Eradication (PLoS ONE (2012) 7:11 (e47396) DOI: 10.1371/journal.pone.0047396);Overexpression of miR-142-5p and miR-155 in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Resistant to Helicobacter pylori Eradication

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Saito, Yoshimasa ^a,d   Suzuki, Hidekazu ^a   Tsugawa, Hitoshi ^a   Imaeda, Hiroyuki ^a   Matsuzaki, Juntaro ^a   Hirata, Kenro ^a   Hosoe, Naoki ^a   Nakamura, Masahiko ^c   Mukai, Makio ^b   Saito, Hidetsugu ^a,d   Hibi, Toshifumi ^a  

^a Department of Internal Medicine   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; MICRORNA; MICRORNA 142 5P; MICRORNA 155; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; API2 MALT1 GENE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; ERADICATION THERAPY; FEMALE; GASTRIC MARGINAL ZONE LYMPHOMA; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; HELICOBACTER HEILMANNII; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MALE; MARGINAL ZONE LYMPHOMA; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; RNA GENE; STOMACH CANCER; TNP53INP1 GENE; TREATMENT OUTCOME;

EID: 84870329062     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0278797     Document Type: Erratum

References (35)

1. Sackmann M, Morgner A, Rudolph B, Neubauer A, Thiede C, et al. (1997) Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. Gastroenterology 113: 1087-1090.
2. Ruskone-Fourmestraux A, Lavergne A, Aegerter PH, Megraud F, Palazzo L, et al. (2001) Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 48: 297-303.
3. Suzuki H, Hibi T, Marshall BJ, (2007) Helicobacter pylori: present status and future prospects in Japan. J Gastroenterol 42: 1-15.
4. Akagi T, Motegi M, Tamura A, Suzuki R, Hosokawa Y, et al. (1999) A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 18: 5785-5794.
5. Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, et al. (1999) The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93: 3601-3609.
6. Liu H, Ye H, Ruskone-Fourmestraux A, De Jong D, Pileri S, et al. (2002) T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 122: 1286-1294.
7. Motegi M, Yonezumi M, Suzuki H, Suzuki R, Hosokawa Y, et al. (2000) API2-MALT1 chimeric transcripts involved in mucosa-associated lymphoid tissue type lymphoma predict heterogeneous products. Am J Pathol 156: 807-812.
8. Hosokawa Y, Suzuki H, Suzuki Y, Takahashi R, Seto M, (2004) Antiapoptotic function of apoptosis inhibitor 2-MALT1 fusion protein involved in t(11;18)(q21;q21) mucosa-associated lymphoid tissue lymphoma. Cancer Res 64: 3452-3457.
9. Farinha P, Gascoyne RD, (2005) Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 23: 6370-6378.
10. He L, Hannon GJ, (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531.
11. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, et al. (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801.
12. Calin GA, Croce CM, (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866.
13. Saito Y, Suzuki H, Hibi T, (2009) The role of microRNAs in gastrointestinal cancers. J Gastroenterol 44 Suppl 19: 18-22.
14. Cho WC, (2010) MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 42: 1273-1281.
15. Cho WC, (2010) MicroRNAs in cancer- from research to therapy. Biochim Biophys Acta 1805: 209-217.
16. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, et al. (2006) Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9: 435-443.
17. Saito Y, Jones PA, (2006) Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 5: 2220-2222.
18. Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, et al. (2009) Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun 379: 726-731.
19. Saito Y, Suzuki H, Tsugawa H, Nakagawa I, Matsuzaki J, et al. (2009) Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. Oncogene 28: 2738-2744.
20. Eis PS, Tam W, Sun L, Chadburn A, Li Z, et al. (2005) Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A 102: 3627-3632.
21. Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A, (2004) High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer 39: 167-169.
22. Nakamura M, Murayama SY, Serizawa H, Sekiya Y, Eguchi M, et al. (2007) "Candidatus Helicobacter heilmannii" from a cynomolgus monkey induces gastric mucosa-associated lymphoid tissue lymphomas in C57BL/6 mice. Infect Immun 75: 1214-1222.
23. Chen CZ, Li L, Lodish HF, Bartel DP, (2004) MicroRNAs modulate hematopoietic lineage differentiation. Science 303: 83-86.
24. Ramkissoon SH, Mainwaring LA, Ogasawara Y, Keyvanfar K, McCoy JP Jr, et al. (2006) Hematopoietic-specific microRNA expression in human cells. Leuk Res 30: 643-647.
25. Calin GA, Croce CM, (2006) MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 25: 6202-6210.
26. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, et al. (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7: 1630-1636.
27. Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, et al. (2012) Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 61: 507-513.
28. Akamatsu T, Mochizuki T, Okiyama Y, Matsumoto A, Miyabayashi H, et al. (2006) Comparison of localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma with and without Helicobacter pylori infection. Helicobacter 11: 86-95.
29. Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, et al. (2007) Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A 104: 16170-16175.
30. Lewis BP, Burge CB, Bartel DP, (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
31. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834-838.
32. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198.
33. Fang C, Zhu DX, Dong HJ, Zhou ZJ, Wang YH, et al. (2012) Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. Ann Hematol 91: 553-559.
34. Tomasini R, Seux M, Nowak J, Bontemps C, Carrier A, et al. (2005) TP53INP1 is a novel p73 target gene that induces cell cycle arrest and cell death by modulating p73 transcriptional activity. Oncogene 24: 8093-8104.
35. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, et al. (2005) Silencing of microRNAs in vivo with 'antagomirs'. Nature 438: 685-689.